Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Intravascular Lymphoma with Central Nervous System Involvement: Mayo Clinic Experience
Neuro-oncology
P4 - Poster Session 4 (11:45 AM-12:45 PM)
5-023

Intravascular lymphoma is a rare hematologic malignancy, which commonly presents with CNS and skin involvement. There is an incomplete understanding of the typical clinical course, treatment, and outcomes.

Characterize the disease course, imaging/laboratory features and clinical outcomes of pathologically confirmed intravascular lymphoma with central nervous system (CNS) involvement.

We retrospectively reviewed our institutional experience of patients with pathologically confirmed intravascular lymphoma (October 1998-November 2019, last review October 2023). Clinical and pathology data were collected from the electronic medical record. Clinical images were reviewed by a neuroradiologist. We performed descriptive statistics. Survival analyses were performed using the Kaplan Meier method.

We identified 22 patients with CNS involvement of intravascular lymphoma. The median age at diagnosis was 63 years (range: 39-79) with 46% female. Median follow-up was 2.6 years (range: 0.04-17.3). The most common symptoms at presentation were focal neurologic deficit including stroke (73%), constitutional symptoms (59%), cognitive changes (27%), personality changes (18%). Lactate dehydrogenase (LDH) was elevated in most patients (90%, mean 634 units/L). Abnormalities on brain MRI were found in 79% of patients, relative to abnormalities on spine MRI (27%) or angiogram (40%). The most common imaging findings were T2 FLAIR abnormalities (74%), mass-like enhancement (42%), ischemic infarct (26%), meningeal enhancement (26%), and susceptibility weighted changes (5%). CSF cytology was rarely positive for malignancy (6%). The most common first-line therapies were R-CHOP (38%) and R-CHOP+MTX (33%). Median overall survival was 3.8 years (95% CI: 0.8-NA).  

Patients with CNS involvement of intravascular lymphoma present variably, including with constitutional symptoms and elevated LDH as seen in systemic-only involvement. Abnormalities on brain MRI are common but not necessarily seen. When present, characteristic imaging findings included T2 FLAIR abnormalities and mass-like enhancement. CSF cytology was rarely positive for malignancy. As expected, overall prognosis remains guarded.

Authors/Disclosures
Bryan J. Neth, MD, PhD (Mayo Clinic)
PRESENTER
Dr. Neth has nothing to disclose.
Ugur Sener, MD (Mayo Clinic) Dr. Sener has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier Pharmaceuticals.
Zafer Keser, MD (Mayo Clinic) Dr. Keser has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier Practice Update.
Derek Johnson, MD (Mayo Clinic) Dr. Johnson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix.
David N. Abarbanel, MD (Mayo Clinic) Dr. Abarbanel has nothing to disclose.
Rafid Mustafa, MD (Mayo Clinic, Department of Neurology) Dr. Mustafa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Mustafa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PicnicHealth.
Jonas Paludo (Mayo Clinic) No disclosure on file
Stephen Ansell No disclosure on file
Robert D. Brown, Jr., MD, MPH, FAAN (Mayo Clinic) Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Craig H Neilsen Foundation. The institution of Dr. Brown has received research support from National Institutes of Health/NINDS. Dr. Brown has received publishing royalties from a publication relating to health care.
Michel Toledano, MD (Mayo Clinic) Dr. Toledano has nothing to disclose.